Martek signs formula deal with Medici Medical

By staff reporter

- Last updated on GMT

Related tags: Dha, Infant, Pediatrics, Milk

Martek Biosciences has signed a license agreement that enables
Medici Medical to use its DHA and ARA in infant formulas sold in

Formulas containing the US-based company's DHA (docosahexaenoic acid) and ARA (arachidonic acid), derived from micro-algae, are already sold in more than 60 countries around the world through licensees.

Martek claims that is DHA and ARA are in 80% of US infant formula. Other licensees include Mead Johnson, Wyeth, Abbott Laboratories and Nestle.

"It is heartening to know that with every new license agreement, more and more infants around the world will benefit from martek's DHA and ARA,"​ said Martek chairman and CEO Henry Linsert.

Both DHA and ARA occur naturally in breast milk, and a body of research has suggested that both fatty acids have a role to play in cognitive and visual development.

A study conducted at Baylor College of Medicine in Houston last year also indicated that babies whose mothers supplement their diet with DHA have improved psychomotor skills as toddlers.

Related news

Show more

Related products

show more

The Ingredients Show 2019 NEC Birmingham

The Ingredients Show 2019 NEC Birmingham

William Reed | 01-Jan-2019 | Product Brochure

We’ve been bringing food and drink markets together for over 150 years. And the drive to
inform and serve our sectors that fuelled the launch of...

Omegavie® DHA algae Capsules

Omegavie® DHA algae Capsules

POLARIS | 23-Aug-2018 | Application Note

Omegavie® DHA algae capsules is a real opportunity to consume high-performing Omega-3 DHA 100% vegan, natural, sustainable, GMO- and allergen-free. Designed...

Related suppliers

Follow us

Featured Events

View more


View more